Question explored with the scientific record
Is DIPG a rare side effect of any Covid 19 vaccines what about in any of the product monographshave dipg rates increased in the last 5 years
No evidence in the retrieved records shows DIPG as a side effect of any COVID-19 vaccine, and no product monographs are discussed.
The retrieved studies do not mention DIPG in connection with any COVID-19 vaccine. One study reports two cases of hematologic malignancies (lymphomas) diagnosed shortly after mRNA vaccination [1], and another describes a brain lesion called cytotoxic lesions of the corpus callosum (CLOCC) after a third dose [2]. Neither is DIPG. The records also contain no product monographs for any COVID-19 vaccine, so nothing in this retrieval speaks to what those documents list.
On whether DIPG rates have increased in the last five years, the evidence is silent. The retrieved studies cover DIPG treatment and biology [3, 4, 5, 6, 7, 8, 9, 10, 11], but none track population incidence over time. One study established the International DIPG Registry, which enrolled 670 patients as of 2017 [9], but that is a count of enrolled cases, not a population rate. Without a study comparing DIPG incidence before and after 2020, this retrieval cannot answer whether rates have changed.
My call: the retrieved evidence does not support a link between COVID-19 vaccines and DIPG, and it provides no data on whether DIPG rates have risen. Confidence: not clear.
Sources used 11
-
Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases
This study presents two cases of hematologic malignancies diagnosed shortly after mRNA COVID-19 vaccination, highlighting the need for vigilance in monitoring potential adverse effects of vaccines in patients with pre-existing conditions.
DOI: 10.3390/medicina58070874 -
CLOCC Patient after COVID-19 (BNT162b) Vaccine Improved by Steroid Treatment
This case report documents a healthy 20-year-old man who developed cytotoxic lesions of the corpus callosum (CLOCC) after the third COVID-19 vaccine (BNT162b), presenting with fever and altered mentation, who rapidly improved with high-dose corticosteroids and recovered without …
DOI: 10.17340/jkna.2022.3.5 -
The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials
This study reports the results of two Phase I clinical trials evaluating the safety and preliminary efficacy of the oncolytic adenovirus Ad-TD-nsIL12 in pediatric patients with IDH wild-type diffuse intrinsic pontine glioma, demonstrating safety and some evidence of efficacy in …
DOI: 10.1038/s41467-025-62260-5 -
Prospective Evaluation of Radiotherapy With Concurrent and Adjuvant Temozolomide in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
This study evaluates the outcomes of radiotherapy combined with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma, revealing no significant improvement in survival compared to radiotherapy alone.
DOI: 10.1016/j.ijrobp.2009.04.031 -
Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma
This study evaluates the efficacy and toxicity of radiation therapy combined with temozolomide chemotherapy in children with diffuse intrinsic pontine glioma, finding no significant improvement in outcomes compared to radiotherapy alone and highlighting the associated higher tox…
DOI: 10.1007/s11060-011-0681-7 -
Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment
This study establishes a human glioma cell line derived from a surgical biopsy of a diffuse intrinsic pontine glioma (DIPG) patient, demonstrating its tumorigenic potential in athymic rats and providing a valuable model for future therapeutic investigations.
DOI: 10.1007/s11060-012-0973-6 -
Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma
This study identifies recurrent activating mutations in the ACVR1 gene in diffuse intrinsic pontine glioma (DIPG), suggesting new therapeutic targets for this otherwise incurable disease.
DOI: 10.1038/ng.2925 -
Radiation and subsequent reirradiation outcomes in the treatment of diffuse intrinsic pontine glioma and a systematic review of the reirradiation literature
This study reviews the outcomes of radiation therapy and subsequent reirradiation in patients with diffuse intrinsic pontine glioma (DIPG), highlighting the poor prognosis and potential for palliative care through reRT.
DOI: 10.1016/j.prro.2016.11.005 -
The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease
The study presents the establishment and operational framework of the International Diffuse Intrinsic Pontine Glioma Registry (IDIPGR), which aims to enhance collaborative research and improve outcomes for patients with this rare and aggressive brain tumor by providing a central…
DOI: 10.1007/s11060-017-2372-5 -
A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas
This phase II trial evaluated the efficacy of capecitabine rapidly disintegrating tablets combined with radiation therapy in improving progression-free survival in children with newly diagnosed diffuse intrinsic pontine gliomas, but found no significant improvement in outcomes c…
DOI: 10.1002/pbc.26832 -
Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS)
This study presents a validated liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) method for the sensitive quantification of vandetanib in human plasma and cerebrospinal fluid, crucial for understanding its pharmacokinetics in pediatric patien…
DOI: 10.1016/j.jchromb.2011.07.012